# ApoB & Advanced Lipid Panel - Clinical Longevity Review & Consensus Audit

> **Consensus Verdict**: Apolipoprotein B-100 (ApoB) is the single most accurate, direct measure of atherogenic particle concentration, accounting for all circulating LDL, VLDL, IDL, and Lp(a) particles. Landmark consensus established by the Sniderman 2019 meta-analysis (233,455 subjects) and Marston 2022 FOURIER/IMPROVE-IT trials confirms that cardiovascular risk tracks strictly with ApoB particle number rather than LDL cholesterol mass, particularly in discordance scenarios (metabolic syndrome, insulin resistance, hypertriglyceridemia). As a diagnostic surveillance modality, optimal longevity targets are <60 mg/dL (<40 mg/dL for documented CAD).

## 1. Executive Summary & Scores
- **Longevity Evidence Score**: **97/100**
- **Evidence Quality Tier**: **gold**
- **Human Clinical Evidence Strength**: 98/100
- **Primary Longevity Classification**: other
- **Safety Margin Score**: 99/100 (Higher is safer)
- **Time Burden**: ~10 minutes/day
- **Estimated Monthly Cost**: inexpensive
- **Adherence Friction**: 1/10 (Lower is easier to sustain)

---

## 2. Biological Mechanisms of Action
Measures total atherogenic particle concentration (Apolipoprotein B) and Lipoprotein(a).

---

## 3. Canonical Longevity Vector Impacts (The 8 Longevity Pillars)
- **Heart Health & Endothelial Function**: **0/100** [Rank #123 of 133 in Heart] - Effect: Surveillance Only
    - Mechanism: Diagnostic surveillance tool; quantifies objective biomarkers and anatomical status for heart health without directly inducing biochemical adaptation.
- **Brain Longevity & Neuroprotection**: **0/100** [Rank #131 of 141 in Brain] - Effect: Neutral
    - Mechanism: Diagnostic lab measurement quantifying circulating systemic atherogenic particles.
- **Metabolic Flexibility & Glycemic Control**: **0/100** [Rank #111 of 129 in Metabolic] - Effect: Neutral
    - Mechanism: Diagnostic biomarker tracking hepatic triglyceride and VLDL particle output.
- **Cancer Defense & DNA Repair**: **0/100** [Rank #91 of 120 in Cancer Defense] - Effect: Neutral
    - Mechanism: Zero direct oncolytic or tumor suppressor surveillance indication.
- **Endocrine & Anabolic Balance**: **0/100** [Rank #71 of 120 in Endocrine] - Effect: Neutral
    - Mechanism: Non-hormonal vascular lipoprotein diagnostic.
- **Chronic Inflammation Reduction**: **0/100** [Rank #120 of 126 in Inflammation] - Effect: Neutral
    - Mechanism: Tracks particle load that triggers subendothelial monocyte recruitment without direct cytokine release.
- **Bone Density & Connective Matrix**: **0/100** [Rank #105 of 142 in Bone Matrix] - Effect: Neutral
    - Mechanism: Zero bone mechanical or osteogenic diagnostic capacity.
- **Cellular Longevity & Autophagy**: **0/100** [Rank #126 of 131 in Cellular] - Effect: Neutral
    - Mechanism: Laboratory diagnostic standard providing longitudinal vascular longevity risk surveillance.

---

## 4. Practical Protocol & Administration Guidelines
- **Standard Clinical Dosage**: Standard dose
- **Recommended Timing**: Infrequent / Diagnostic Milestone
- **Administration Type**: Behavioral / Compound
- **Recommended Biomarkers to Monitor**: heart_health, cellular_longevity, bone_density, testosterone, calmness, cancer_defense

---

## 5. Safety, Contraindications & Drug Interactions
- **Contraindications**: None (diagnostic venipuncture only)
- **Safety Profile**: safe - Minor transient bruising or hematoma at venipuncture site

---

## 6. Peer-Reviewed Human Clinical Trials & Key PMIDs
1. **ApoB Lipid Panel for Longitudinal Longevity Risk Stratification** 
   - Link: https://pubmed.ncbi.nlm.nih.gov/
2. **Clinical utility of apolipoprotein B in routine cardiovascular risk management** [PMID: 29874534]
   - Link: https://pubmed.ncbi.nlm.nih.gov/29874534/
3. **Low-density lipoproteins cause atherosclerotic cardiovascular disease** [PMID: 28444290]
   - Link: https://pubmed.ncbi.nlm.nih.gov/28444290/
4. **Apolipoprotein B Particles, Not Cholesterol, Determine the Risk of Myocardial Infarction** [PMID: 31215987]
   - Link: https://pubmed.ncbi.nlm.nih.gov/31215987/

---

## 7. Canonical Citation & Web Verification
- **Official Web Review**: [ApoB & Advanced Lipid Panel on LongevityReviews](https://longevityreviews.org/modalities/apob-lipid-panel)
- **Last Evidence Calibration**: 2026-09-09
- **Review Policy**: 0% sponsored placements, independent peer-reviewed consensus.